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Abstract 
Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising anti-
tumour agent that induces apoptosis of malignant cells through activation of death receptors.  
Death receptor agonistic antibodies are in clinical trials as TRAIL-mimetics, however, along 
with TRAIL monotherapy, show limited efficacy due to the rapid emergence of TRAIL-
insensitive disease.  TRAIL-sensitisers, which enhance TRAIL activity or overcome TRAIL 
resistance, may facilitate death receptor agonists as viable anti-tumour strategies.  In this 
study we demonstrate that the nuclear export inhibitor, Leptomycin B, is a potent in vitro 
TRAIL-sensitiser in osteosarcoma.  Leptomycin B works synergistically with both TRAIL 
and death receptor 5 agonistic antibodies to induce apoptosis in TRAIL sensitive cell lines.  
Further, Leptomycin B sensitises TRAIL-insensitive cell lines to TRAIL and death receptor 
agonistic antibody mediated apoptosis.  We also confirmed that aldehyde dehydrogenase 
(ALDH) positive cells are not resistant to the apoptotic effects of TRAIL and Leptomycin B, 
an important observation since ALDH positive cells can have enhanced tumorigenicity and 
are implicated in disease recurrence and metastasis.  The nuclear export pathway, in 
combination with death receptor agonists, is a potential therapeutic strategy in osteosarcoma 
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Osteosarcoma is the most prevalent primary bone malignancy.  It shows a bimodal age 
distribution affecting a significant number of adolescents and young adults, as well as those 
aged >55 years.  In younger patients, osteosarcoma commonly occurs at the metaphysis of 
lower extremity long bones and has been associated with hormonal change and bone growth, 
whereas in older patients disease may also develop in other primary bone locations [1]. 
Current treatment consists of surgery with adjuvant radiotherapy and chemotherapy yet 
despite surgical advancements, survival rates remain largely unchanged in recent decades [2].  
In adolescents the survival rate for high grade osteosarcoma is ~60% at 5 years [3] although 
this is drastically reduced in late stage and metastatic patients.  Late stage diagnosis is 
common and therapeutic agents that target local recurring tumours and metastases need to be 
identified. 
Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is a member of the tumour 
necrosis factor family that extrinsically induces apoptosis through binding of death receptor 4 
or 5 (DR4 or DR5) to initiate a caspase cascade [4].  TRAIL can also bind to decoy receptors 
(DcR1 and DcR2) and osteoprotegerin (OPG) thus inhibiting death inducing signalling [5-7].  
Therapeutic monoclonal antibodies specific to DR4 or DR5 are shown to induce apoptosis of 
malignant cells and to bypass DcRs and OPG [8] which offers a potential mechanism to 
overcome inhibition of death receptor signalling.  However, evaluation of TRAIL and 
agonists of DR4/DR5 in clinical trials showed limited anti-tumour efficacy due to rapid 
emergence of TRAIL-resistant disease [9-10], mirroring in vitro observations [11-12].    
Exportin-1 (XPO1) is a nucleo-cytoplasmic transporter responsible for exporting nuclear 
proteins into the cytoplasm from the nucleus.  XPO1 cargo include growth regulatory and 
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 Aldehyde dehydrogenase (ALDH), Cancer stem cell (CSC), Death receptor (DR), Decoy receptor (DcR), Flow 
Activated Cell Sorting (FACS), Osteoprotegerin (OPG), Exportin-1 (XPO1), selective inhibitor of nuclear 
export (SINE), Tumour necrosis factor-related apoptosis inducing ligand (TRAIL)  
tumour suppressor proteins such as FOXO, STAT3, APC, Rb1, p53 and p21.  XPO1 is over-
expressed in osteosarcoma [13] and other cancers including glioma, pancreatic cancer and 
haematological conditions [14].  XPO1 overexpression increases exportation of tumour 
suppressor proteins inhibiting suppressive activity even in the presence of DNA damage and 
faulty DNA repair mechanisms [15].  As such, inhibiting nuclear export has the potential to 
re-establish tumour suppression and may offer therapeutic benefit.   
Leptomycin B is a well-characterised inhibitor of XPO1 which is widely used in cellular 
studies of protein trafficking and has been used to assess apoptotic responses in vitro [16, 17].  
Leptomycin B monotherapy has previously been used in a Phase I trial as an anti-tumour 
agent [18].  In this study, we investigated the apoptotic effects of Leptomycin B in 
combination with TRAIL and agonistic death receptor antibodies.  Further, we investigated 
whether aldehyde dehydrogenase (ALDH) positive osteosarcoma cells were resistant to the 
apoptotic effects of TRAIL and/or Leptomycin B. ALDH activity is associated with cancer 
stem cell (CSC) phenotype and drug resistance in other sarcomas [19-21].  Furthermore, 
ALDH correlates with metastatic potential in osteosarcomas [22] and has been identified as a 
CSC marker in cultured osteosarcoma cells [23]. To date, no studies have addressed TRAIL 
sensitisation by nuclear export inhibitors, or the potential role of ALDH+ cells in mediating 
TRAIL-insensitivity in osteosarcomas.      
  
Materials and Methods 
MG63, Soas-2 and U2-OS human osteosarcoma cell lines were obtained from ATCC and 
maintained in basal media (MG63 – RPMI 1640; Saos-2 – MEM-alpha with nucleosides; U2-
OS – McCoys 5A) supplemented with 10% foetal bovine serum, 2mM L-glutamine, 100 
U/mL penicillin and 100 µg/mL streptomycin.  RPMI-1640 was further supplemented with 
1% non-essential amino acids.  Cultures were maintained at 37°C, 5% CO2.     
Microscopic assessment of apoptosis  
96-well plates were seeded with 2.0 x 10
4
 cells/well (MG63 & U2-OS) or 4.0 x 10
4
 cells/well 
(Saos-2) and allowed to settle overnight prior to treatment with 0 - 50 ng/mL rhTRAIL 
(PeproTech EC Ltd, London, UK) or 0 - 50 ng/mL anti-DR5 monoclonal antibody (Mab631, 
R&D Systems, Abingdon, UK) and/or 0 - 20 nM Leptomycin B (Enzo Life Sciences, Exeter, 
UK) for 24 hours.  Induction of apoptosis was assessed by staining cells with 10 µg/mL 
Hoechst 33342 and 10 µg/mL Propidium Iodide (PI; Sigma, Poole, UK) at 37°C for 30 
minutes.  Cultures were visualised using an Olympus IX81 inverted fluorescent microscope 
and images captured using Cell-F software (Olympus, Tokyo, Japan).  Apoptosis was 
determined manually by assessment of nuclear morphology.  Cells were counted and percent 
apoptosis calculated from duplicate representative fields of view from each well, each 
containing at least 200 cells.  All treatment combinations were performed in triplicate, and in 
at least 3 independent experiments.  Statistical analysis was performed using one-way 
ANOVA with Dunnett post-hoc test for single treatments, or two-way ANOVA with Holm-
Sidak post-hoc test for combination treatments using Prism v6.07 software (GraphPad 
Software Inc., CA, USA).      
NucView Caspase-3 activity assay  
Cells were seeded to 96 well plates and subjected to 24 hour treatment with TRAIL, anti-DR5 
and/or Leptomycin B as described above.  NucView Caspase-3 activity assay (Biotium, 
Cambridge Biosciences, Cambridge, UK) was performed as per manufacturer’s instructions 
for flow cytometry analysis.  Briefly, cells were stained with 0.2 mM NucView Caspase-3 
substrate and incubated at room temperature for 20 minutes.  Data was collected using a 
Gallios flow cytometer (Beckman Coulter, High Wycombe, UK) measuring fluorescence 
emission at 525 nm (FL1).  Assay control samples were prepared by pre-incubation of cells 
with the irreversible inhibitor of caspase-3, Z-DEVD-FMK, at 37°C for 20 minutes prior to 
addition of NucView Caspase-3 substrate.  Inhibitor concentrations were determined 
empirically for each cell line: 100 μM for MG63, 200 μM for Saos-2 and 100 μM for U2-OS.  
Statistical analysis was performed using one-way ANOVA with Dunnett post hoc test using 
Prism v6.07 software.             
Aldehyde dehydrogenase activity assay and cell sorting  
ALDH activity assay was performed using ALDEFLUOR kit (Stemcell Technologies, 
Cambridge, UK) as per manufacturer’s instructions.  Briefly, cells were stained in 0.61 
μg/mL Aldefluor substrate in Aldefluor buffer at 37°C for 30 minutes.  Following staining, 
cells were washed and re-suspended in Aldefluor buffer supplemented with the efflux 
inhibitor, verapamil (200 μM), and kept on ice for cell sorting.  Assay control samples were 
prepared by addition of the ALDH inhibitor, diethylaminobenzaldehyde (DEAB).  Cells were 
sorted using a FACSARIA flow cytometer (BD, Wokingham, UK) measuring fluorescence 
emitted at 525 nm (FL1).  ALDH positive cells were those emitting fluorescence greater than 
inhibitor-treated control cells.  ALDH
 
positive and ALDH negative populations were 
collected, washed, assessed by trypan blue exclusion for ≥95% viability, seeded to 96-well 
plates and subjected to 24-hour treatment with TRAIL, anti-DR5 and/or Leptomycin B as 
described previously.  Induction of apoptosis was assessed microscopically following 
Hoechst 33342 and PI staining as described above.  Statistical analysis was performed using 
two-way ANOVA with Holm-Sidak post-hoc test using Prism v6.07 software.    
Results 
We assessed sensitivity to TRAIL and anti-DR5 in MG63, Saos-2 and U2-OS cell lines 
(Figure 1) by Hoechst 33342 and PI nuclear staining.  MG63 were exquisitely sensitive to 
TRAIL with significant induction of apoptosis at ≥2 ng/mL stimulation.  Induction of 
apoptosis was observed in approximately 80% of MG63 cells with 50 ng/mL TRAIL 
treatment.  MG63 were also sensitive to anti-DR5 although to a lesser extent than TRAIL, 
with significant induction of apoptosis at ≥10 ng/mL stimulation.  Apoptosis was observed in 
approximately 40% of MG63 cells using 50 ng/mL anti-DR5 treatment.  Saos-2 were 
sensitive to TRAIL only at concentrations ≥25 ng/mL and insensitive to anti-DR5 at all 
concentrations investigated.  Maximum dose TRAIL stimulation (50 ng/mL) induced 
apoptosis in approximately 20% of Saos-2 cells.  U2-OS were sensitive to TRAIL and anti-
DR5 stimulation with significant induction of apoptosis at ≥ 10 ng/mL.  Induction of 
apoptosis was observed in approximately 30% of cells using 50 ng/mL TRAIL treatment and 
10% of cells with 50 ng/mL anti-DR5.  Baseline assessment of TRAIL and anti-DR5 
sensitivity indicated that TRAIL was the more potent inducer of apoptosis in the 3 cell lines 
investigated.  
To determine whether the nuclear export inhibitor Leptomycin B could effectively sensitise 
osteosarcoma cells to TRAIL or anti-DR5 we performed combination treatment experiments.  
A concentration of TRAIL that was shown in our previous experiments to induce <30% 
apoptosis was selected for each cell line; 50 ng/mL for Saos-2 and 25 ng/mL for U2-OS.  
Additional titration of low dose TRAIL was performed on MG63 using 0.125, 0.25, 0.50, 1.0 
and 2.0ng/mL (data not shown) based on the high TRAIL sensitivity observed for this cell 
line.  Stimulation with 0.25 ng/mL induced significant apoptosis in approximately 10% of 
MG63 cells and was selected for use in combination experiments.  Matched concentrations of 
anti-DR5 were used to determine the differential sensitivity between the DR4 and DR5 
agonist, TRAIL, and anti-DR5 stimulation alone.  
The osteosarcoma cell lines investigated showed only limited sensitivity to Leptomycin B as 
a single agent.  Leptomycin B alone induced significant apoptosis in Saos-2 at ≥2 nM, but not 
in MG63 or U2-OS at any concentration investigated (up to 20 nM) as determined by 
Hoechst 33342 and PI nuclear staining.  Combination treatment with Leptomycin B and 
TRAIL revealed synergy in the induction of apoptosis in all 3 cell lines (Figure 2).  This 
effect was clearly apparent with all concentrations of Leptomycin B and TRAIL investigated.  
Leptomycin B was also seen to enhance the apoptotic activity of anti-DR5 although effect 
sizes were more modest (Figure 2).  To confirm nuclear morphology data, we repeated 
combination treatment experiments for selected Leptomycin B concentrations and measured 
activity of Caspase-3 by flow cytometry.  Low level Caspase-3 activity was observed in 
MG63, Saos-2 and U2-OS in response to high dose Leptomycin B (Figure 3) although 
significant increases in cells with apoptotic nuclear morphology were only recorded in our 
previous experiment in Saos-2.  Combining Leptomycin B with TRAIL or anti-DR5 
dramatically increased Caspase-3 activity.  For MG63, activity was significantly increased 
when 20 nM Leptomycin B was combined with either TRAIL or anti-DR5.  For Saos-2, 
activity was significantly increased when ≥0.5 nM Leptomycin B was combined with either 
TRAIL or anti-DR5.  For U2-OS, activity was significantly increased when ≥0.5 nM 
Leptomycin B was combined with TRAIL, and when 20 nM Leptomycin B was combined 
with anti-DR5.    
Expression of ALDH is associated with cellular pluripotency and may confer stem-like 
characteristics to cancer cells.  To investigate whether sensitivity to Leptomycin B in 
combination with either TRAIL or anti-DR5 is affected by ALDH expression, we separated 
ALDH+ and ALDH- cells by FACS.  In MG63, a significantly lower proportion of ALDH+ 
cells were apoptotic following combination treatment with Leptomycin B and TRAIL when 
compared to ALDH- cells (Figure 4).  This effect was not due to differences in TRAIL 
sensitivity as no significant difference to TRAIL alone was recorded between ALDH+ and 
ALDH- cells.  Further, this effect was not seen when Leptomycin-B was combined with anti-
DR5.  In Saos-2 and U2-OS, there was no differential sensitivity to Leptomycin B in 
combination with either TRAIL or anti-DR5, or to TRAIL or anti-DR5 when used as single 
agents, between ALDH+ and ALDH- cells (Figure 4).  
  
Discussion 
Resistance to TRAIL-based therapies limits the use of rhTRAIL, or agonistic antibodies to 
DR4/5.  It is acknowledged that efficacy is limited with single agent use and that combination 
treatment with TRAIL sensitisers will be required for sustained anti-tumour activity.  Many 
TRAIL sensitisers have been described, including DNA damaging and microtubule inhibiting 
chemotherapies, proteasome inhibitors, and histone deacetylase (HDAC) inhibitors [24, 25].  
Here we describe the nuclear export inhibitor, Leptomycin B, as a potent TRAIL sensitiser in 
osteosarcoma cell lines.  
Leptomycin B inhibits XPO1, therefore trapping cargo molecules within the nucleus.  XPO1 
enhances the malignant phenotype in transformed cells as many cargo molecules, when 
delivered to the cytoplasmic compartment, either limit tumour suppression or enhance 
oncogenic signalling.  Key cargo molecules include the tumour suppressors; p53, p73, APC, 
Rb, FOXO, BRCA1 and NPM1, and the cell cycle regulators; p21, p27 and galectin-3 [16, 
26, 27].  Oncogenic mRNA transcripts such as c-Myc, cyclin D1 and MDM2 are also cargo 
and delivery to the cytoplasm enhances oncoprotein production [28].  As such, interest in the 
therapeutic use of nuclear export inhibitors is longstanding.  However, the use of Leptomycin 
B in a single clinical trial in 1996 was associated with dose-limiting toxicity and no responses 
in 33 patients with advanced refractory cancer [18].            
Osteosarcoma cells overexpress XPO1 [13] however, they were not overly sensitive to 
Leptomycin B alone.  Significant induction of apoptosis following single agent treatment was 
recorded only in Saos-2, although all cell lines showed some increase in caspase-3 activity 
with high dose stimulation, which may indicate some re-establishment of tumour suppressive 
or growth regulatory mechanisms.  Whilst single agent use did not lead to significant cell 
death, a potent and synergistic effect was recorded in all cell lines to combination with either 
TRAIL or anti-DR5.  This effect was observed irrespective of TRAIL sensitivity since our 
initial experiments confirmed that MG63 were TRAIL sensitive while Saos-2 and U2-OS 
were not.  Caspase-3 activity confirmed dose-dependent sensitisation of osteosarcoma cells to 
both TRAIL and anti-DR5.  Many mechanisms for nuclear export inhibitor anti-tumour 
activities have been proposed in other cancer types, particularly entrapment of nuclear p53 
driving increased Bax expression whereby dominant negative p53 mutant cells are less 
affected by Leptomycin B than wild-type cells [16, 29].  U2-OS is p53-wild-type, whereas 
Saos-2 is p53-deleted and MG63 is p53-mutant.  All three cell lines were susceptible to 
Leptomycin B sensitisation, suggesting that in osteosarcoma at least, effects are independent 
of p53 status.  Blockade of p27 nuclear export promotes growth arrest in osteosarcoma [30] 
but this alone is unlikely to explain apoptotic responses observed here.  Interestingly, 
Kashyap et al. (2016) demonstrated siRNA knockdown of IκB decreases sensitivity to 
nuclear export inhibition in U2-OS cells [31].  IκB sequesters NF-κB in the cytosol, 
supporting a role for the NF-κB axis in cell survival in response to nuclear export inhibition 
[32].  
Acquired resistance is a major problem of targeted therapies, particularly monotherapies. 
Assessment of agents against both the bulk tumour population and the more tumorigenic 
CSC-like population determines whether the bulk population is preferentially targeted, as in 
the case of DNA damaging agents.  Here we assessed the sensitivity of ALDH positive cells.  
These may represent the CSC-like population [23] and are associated with aggressive 
phenotype, resistance to apoptosis [33], and metastasis [22].  We demonstrated that ALDH 
activity confers no resistance to apoptosis induced by combination treatment of Leptomycin 
B and TRAIL or anti-DR5 in Saos-2 or U2-OS, although ALDH activity in MG63 cells did 
lead to lower induction of apoptosis, however potent TRAIL sensitisation by Leptomycin B 
was seen in ALDH+ cells of all cell lines.  TRAIL sensitisation with nuclear export inhibitors 
could therefore be a potential therapeutic strategy for elimination of tumorigenic 
osteosarcoma cells, although it is unlikely that Leptomycin B could be considered for clinical 
use. Selective inhibitors of nuclear export (SINEs) such as Selinexor, represent the most 
promising therapeutic candidates with improved safety and tolerability in phase I clinical 
trials [15, 34].  Future pre-clinical studies using SINE sensitisation and TRAIL therapeutics is 
therefore warranted.   
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Figure 1.  Apoptosis induction following 24-hour stimulation with TRAIL or anti-DR5 in 
MG63, Saos-2 and U2-OS osteosarcoma cell lines assessed by Hoechst 33342 and PI nuclear 
staining. Data shown is mean ± SEM (n=3), statistics by one-way ANOVA with Dunnett 






Figure 2.  Apoptosis induction following 24-hour stimulation with Leptomycin B in the 
presence and absence of TRAIL or anti-DR5 in MG63 (0.25 ng/mL), Saos-2 (50 ng/mL) and 
U2-OS (25 ng/mL) osteosarcoma cell lines assessed by Hoechst 33342 and PI nuclear 
staining.  a) Data shown is mean ± SEM (n=3), statistics by two-way ANOVA with Holm-
Sidak post-hoc test.  * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001; ### 
indicates significant induction of apoptosis by Leptomycin B alone compared to untreated 
control (p<0.001).  b) Representative Hoechst 33342 and PI staining of US-OS cells in 
response to vehicle control, TRAIL (25ng/mL) Leptomycin B (20 nM), TRAIL + LMB, anti-
DR5 (25ng/mL) and anti-DR5 + Leptomycin B. LMB = Leptomycin B 
  
 
Figure 3.  Caspase 3 activity following 24-hour stimulation with Leptomycin B in the 
presence and absence of TRAIL or anti-DR5 in MG63, Saos-2 and U2-OS osteosarcoma cell 
lines.  Data shown is mean ± SEM (n=3), statistics by one-way ANOVA with Dunnett post-
hoc test.  * indicates p<0.05. ** indicates p<0.01, *** indicates p<0.001 compared to 0nM 
control.   
  
 
Figure 4.  Apoptosis induction following 24-hour stimulation with Leptomycin B in the 
presence and absence of TRAIL or anti-DR5 in FACS-sorted ALDH- and ALDH+ MG63, 
Saos-2 and U2-OS osteosarcoma cell lines, assessed by Hoechst 33342 and PI nuclear 
staining.  Data shown is mean ± SEM (n=3), statistics by two-way ANOVA with Holm-Sidak 
post-hoc test.  * indicates p<0.05. ** indicates p<0.01, *** indicates p<0.001 compared to 
0nM control.  ## indicates significant difference between ALDH- and ALDH+ cells (p<0.01). 
 
 
